We are currently studying itolizumab in a number of clinical trials in diseases where immuno-inflammation plays a role, including graft-versus-host disease, uncontrolled moderate to severe asthma, and SLE / lupus nephritis.
To learn more about our ongoing clinical trials please visit www.clinicaltrials.gov and search “EQ001” or email clinicaltrials@equilliumbio.com.
The EQUATE study
A Phase 1b Dose-Escalation Study of Intravenous Itolizumab (EQ001) in Subjects With Acute Graft-Versus-Host Disease
The EQUALISE Study
A Phase 1b, Multiple-Ascending-dose Study of itolizumab (EQ001) in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis
The EQUIP study
A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Itolizumab (EQ001) in Subjects With Moderate to Severe Uncontrolled Asthma